↓ Skip to main content

Dove Medical Press

Article Metrics

The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controll…

Overview of attention for article published in Neuropsychiatric Disease and Treatment, June 2021
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (53rd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
15 Mendeley
Title
The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials
Published in
Neuropsychiatric Disease and Treatment, June 2021
DOI 10.2147/ndt.s312011
Pubmed ID
Authors

Azmi Nasser, Joseph T Hull, Tesfaye Liranso, Gregory D Busse, Zare Melyan, Ann C Childress, Frank A Lopez, Jonathan Rubin

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 3 20%
Student > Master 3 20%
Professor 2 13%
Professor > Associate Professor 1 7%
Other 1 7%
Other 1 7%
Unknown 4 27%
Readers by discipline Count As %
Unspecified 4 27%
Psychology 2 13%
Nursing and Health Professions 1 7%
Pharmacology, Toxicology and Pharmaceutical Science 1 7%
Medicine and Dentistry 1 7%
Other 1 7%
Unknown 5 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2021.
All research outputs
#12,426,487
of 21,463,092 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,186
of 2,865 outputs
Outputs of similar age
#157,281
of 348,517 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#4
of 8 outputs
Altmetric has tracked 21,463,092 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,865 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,517 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.